Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)

NCT00109733 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00109733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00109733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)
Lead sponsor
EMD Serono
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
July 31, 2006
Enrollment
31 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

childhood-onset growth hormone deficiency, pituitary dwarfism